RBR-8nfx26
Not yet recruiting
Phase 2
Inhaled Nitric Oxide for Treatment of SARS-CoV-2 Infection: An Open-Label, Multicenter, Parallel, Randomized Controlled Trial
Pontifícia Universidade Católica do Rio Grande do Sul - PUCRS0 sitesStarted: September 22, 2020Last updated:
Overview
- Phase
- Phase 2
- Status
- Not yet recruiting
- Sponsor
- Pontifícia Universidade Católica do Rio Grande do Sul - PUCRS
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Intervention
Eligibility Criteria
- Ages
- 10 to 100 (—)
Inclusion Criteria
- •Hospitalized patients with proven or high suspicion of coronavirus infection; signing a consent form and/or assent; older than 10 years. Score clinical 4 (receiving supplemental oxygen).
- •Non hospitalized patients with proven or high suspicion of coronavirus infection; signing a consent form and/or assent; older than 10 years. Score clinical 2 (at home with limitations).
Exclusion Criteria
- •Participant in any other clinical trial of an experimental treatment for COVID\-19; pregnancy; clinical contraindication of the attending physician; use of a nitric oxide donor agent, such as nitroglycerin or drugs known to increase methaemoglobin, such as lidocaine, prilocaine, benzocaine or dapsone; heart failure, left ventricular dysfunction; history of hemoptysis.
- •Participant in any other clinical trial of an experimental treatment for COVID\-19; Pregnancy; clinical contraindication of the attending physician; indication for hospitalization at the time of evaluation; use of a nitric oxide donor agent, such as nitroglycerin or drugs prepared by increasing methemoglobin, such as lidocaine, prilocaine, benzocaine, or dapsone; heart failure, left ventricular dysfunction; hx of hemoptysis.
Investigators
Similar Trials
Completed
Phase 2
Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19SARS (Severe Acute Respiratory Syndrome)CoronavirusNCT04306393Massachusetts General Hospital200
Active, not recruiting
Phase 1
Pulsed, inhaled nitric oxide (iNO) for the treatment of patients with mild ormoderate corona virus disease (COVID-19)EUCTR2020-002394-94-BEDr. De Backer Wilfried BV6
Active, not recruiting
Phase 1
Therapy with Inhaled Nitric Oxide for Patients Infected with Coronavirus Suffering form Lung FailureARDS caused by COVID-19 infectionTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2020-001329-30-ATMassachussetts General Hospital200
Active, not recruiting
Phase 1
Inhaled Nitric Oxide Gas Therapy in Respiratory Treated Patients with COVID-19 infectioCOVID-19 infection caused by SARS-CoV-2MedDRA version: 20.0Level: LLTClassification code 10038700Term: Respiratory infectionSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2020-001490-68-SEStockholm County Council; Danderyd Hospital40
Completed
Phase 1
High Dose Inhaled Nitric Oxide for COVID-19 (ICU Patients)COVID-19NCT04383002University Health Network, Toronto21